Chemo cocktail aims to shrink sinus tumors and save faces
NCT ID NCT00707473
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This phase II trial tests a combination of three chemotherapy drugs—docetaxel, cisplatin, and fluorouracil—in 31 people with advanced nasal cavity or sinus cancers that have not been treated before. The goal is to shrink tumors enough to allow less radical surgery or radiation, potentially saving the eye or other facial structures. Researchers will track how many patients achieve complete tumor disappearance and whether local control reaches 80%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel, cisplatin, and fluorouracil (chemotherapy drugs)
- What this could lead to
- If successful, this could offer a way to shrink advanced nasal and sinus cancers before other treatments, possibly helping patients avoid losing an eye or part of their face.
- What could go wrong
- This is a small, early-phase trial with only 31 participants. The drugs have significant side effects like infection, kidney damage, and nerve problems. It may not work for everyone or lead to a standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASAL CAVITY AND PARANASAL SINUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.